The Latest Breaking News on Pharma

Walgreens says it will not start selling an abortion pill in 20 states that had warned of legal consequences if it did that

Biopharmaceutical giant Gilead Sciences’ (GILD) shares have risen nearly 30% over the past year despite lingering macroeconomic challenges. Moreover, the company delivered solid growth last year and is expected to maintain its business momentum in 2023 and beyond, driven by its diversified medicines portfolio. Hence, investors could consider buying and…

Victoria is pouring $10 million into training Australia's vaccine workforce, ahead of the southern hemisphere's first mRNA production site opening in 2024.

The Hexham-based start-up is on the hunt for a lead investor to take it into its next funding round

WASHINGTON — Pfizer Inc.’s vaccine for respiratory syncytial virus received endorsement from a key panel of U.S. advisers for its safety in people 60 and older, a key endorsement for the drugmaker’s potential product.

Powerful operating model and consistent execution hailed as record performance revealed

Almost four years after becoming the first state to cap insulin copayments, Colorado may limit what consumers pay for epinephrine autoinjectors, also known as EpiPens, which treat serious allergic reactions.

Healthcare giant Johnson & Johnson (JNJ) has a six-decade-long history of consecutive dividend growth. So, given the uncertainties surrounding the market, this fundamentally strong dividend-paying stock might be an ideal buy now. Read more.

The business will use the new funds to advance development of its microRNA therapeutics